This grant, offered by the National Institutes of Health, is designed to support high-risk, milestone-driven research focused on developing innovative assays. The primary purpose of these assays is to enable the measurement of HIV susceptibility to broadly neutralizing antibodies (bNAbs) within clinical laboratory environments. The funding targets early-stage assay development, requiring proposals to demonstrate feasibility and clinical utility, followed by rigorous verification and late-stage validation of the methods. The initiative strongly encourages collaborative and interdisciplinary research, particularly fostering partnerships between academia and industry, to advance crucial tools for HIV research and clinical management through cutting-edge assay development.
Opportunity ID: 338629
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-AI-22-022 |
| Funding Opportunity Title: | Development of HIV Broadly Neutralizing Antibody Susceptibility Assays (R61/R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.855 — Allergy and Infectious Diseases Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 10, 2022 |
| Last Updated Date: | Mar 10, 2022 |
| Original Closing Date for Applications: | Aug 03, 2022 |
| Current Closing Date for Applications: | Aug 03, 2022 |
| Archive Date: | Sep 08, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | County governments Private institutions of higher education City or township governments For profit organizations other than small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Public and State controlled institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education State governments Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses Special district governments |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This funding opportunity will support high risk, milestone-driven research for the development of innovative assays designed to enable the measurement of HIV susceptibility to broadly neutralizing antibodies (bNAbs) in clinical laboratories. Proposed studies should target early-stage assay development and demonstrate feasibility and clinical utility, followed by verification and late stage validation of the method. Collaborative, interdisciplinary research with partnerships between academia and industry is strongly encouraged. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-22-022.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 338629 Full Announcement-RFA-AI-22-022 -> RFA-AI-22-022-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00272510 | Jul 03, 2022 | Aug 03, 2022 | View |
Package 1
Mandatory forms
338629 RR_SF424_5_0-5.0.pdf
338629 PHS398_CoverPageSupplement_5_0-5.0.pdf
338629 RR_OtherProjectInfo_1_4-1.4.pdf
338629 PerformanceSite_4_0-4.0.pdf
338629 RR_KeyPersonExpanded_4_0-4.0.pdf
338629 RR_Budget_3_0-3.0.pdf
338629 PHS398_ResearchPlan_4_0-4.0.pdf
338629 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
338629 RR_SubawardBudget30_3_0-3.0.pdf
338629 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
